U.S. stock night trading volatility: Stock issuance plan raises dilution concerns, Kyverna Therapeutics plummets 9.43% in after-hours trading

U.S. Stock Night Market Movements Kyverna Therapeutics fell 9.43% in the night market. Based on recent key news: On December 15, Kyverna Therapeutics announced that its experimental cell therapy achieved its primary endpoint in a mid-stage study, leading to a 20% increase in stock price during pre-market trading. The therapy significantly improved patients' walking ability and reduced muscle stiffness. On December 16, the company announced plans for a $100 million stock offering, causing the stock price to drop 6.9% in after-hours trading. This news raised market concerns about equity dilution. On December 15, analysts generally had a positive outlook on Kyverna Therapeutics, raising the target price from $22.50 to $29, reflecting market confidence in the prospects of its cell therapy. The biopharmaceutical industry faces regulatory uncertainties. Stocks with High Trading Volume in the Industry BeiGene fell 1.92% in the night market. Based on recent key news: On December 15, BeiGene recorded significant cross-trade transactions, with the stock price down 6.9% from the previous closing price, leading to a decline in stock price. This transaction involved an amount of 32.63 million yuan, indicating increased selling pressure on the stock, affecting its price downward. On December 15, the market capitalization of innovative pharmaceutical companies in the global healthcare industry significantly increased, and BeiGene, as one of the innovative pharmaceutical companies, faces intensified market competition, affecting its stock performance. The rise in the status of innovative pharmaceutical companies in the global market has weakened investor confidence in traditional pharmaceutical companies. On December 15, the slow progress of reforms in China's healthcare service industry affected BeiGene's sales performance in the domestic market. Medical insurance policies have depressed drug prices, leading to BeiGene's revenue in the Chinese market falling short of expectations, impacting its stock price. The increase in market capitalization of global innovative pharmaceutical companies has intensified competition. Recursion Pharmaceuticals fell 1.67% in the night market, with a trading volume of $804,400, and no significant news recently. The trading was active, with clear capital flow. Considering the sector and industry trends, the stock showed significant volatility, and specific reasons need further observation. Radiopharm Theranostics fell 42.24% in the night market. Based on recent news: On December 15, Radiopharm Theranostics announced that its RAD 101 achieved its primary endpoint in a Phase 2B imaging trial for brain metastases, with 92% of patients showing significant tumor uptake and metabolic activity in the interim analysis. This news led to a 292.72% increase in stock price during pre-market trading, but it subsequently experienced significant volatility. On December 15, the company received approval from Australia to initiate the first human clinical trial of RAD 402 for the treatment of metastatic or locally advanced prostate cancer. Although this news initially drove the stock price up, market uncertainty regarding the trial results led to a subsequent decline in stock price On December 15th, the CEO of Radiopharm Theranostics stated that the combination of RAD 101 PET and standard MRI is expected to improve treatment decisions for patients with brain metastases, with an anticipated market opportunity in the United States exceeding $500 million. However, the market's reaction to this prospect has been mixed, leading to stock price fluctuations. The biotechnology industry has been quite volatile recently, and investors should exercise caution